The U.S. solar manufacturing industry can play an important role in the 21st century economy. But that requires a smart, coherent trade and industrial strategy to counter China.
The United States is facing an unprecedented drug shortage, with a record 323 active drug shortages at the start of 2024 — the highest number since 2001.
Last week, Republicans and Democrats from the Senate’s Joint Economic Committee squared off against each other – with one side arguing in favor of industrial policy programs like the Inflation Reduction Act – and the other side arguing in favor of lower corporate taxes.
The foreign labs in China and India that make the branded drugs for CVS pharmacies nationwide are coming under increased scrutiny for unsafe manufacturing practices.
Will the Pentagon spend $104 million on solar made by a Chinese company? It might be.
The free trade consensus of economists, politicians, and financial pundits operating in polite society is fracturing.
After a generation of making cars with Western automakers, China has evolved into an electric vehicle (EV) force to be reckoned with.
The renewal of the Generalized System of Preferences (GSP) is stuck in limbo in the Senate Finance Committee for now as leading Democrats don’t want to pass it without Trade Adjustment Assistance (TAA).
So what is comparative advantage? Comparative advantage occurs when the ratio of costs in one country differs from the ratio of costs in another.
China’s EV battery companies CATL and Gotion High Tech source materials from companies banned by the U.S. Department of Homeland Security (DHS) due to forced labor violations, the House Select Committee on the Chinese Communist Party said on June 6.
